Fate Therapeutics, Inc.
FATENASDAQHealthcare● Active
$1.91
$-0.07(-3.54%)
Market Cap$222627690
P/E Ratio—
52W High$2.88
52W Low$0.91
Fate Therapeutics, Inc. (FATE) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · FATE · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $6.65M | $13.63M | $63.53M | $96.30M | $55.85M |
| Cost of Revenue | $12.90M | $0.00M | $157.19M | $13.76M | $5.85M |
| Gross Profit | ($6.25M) | $13.63M | ($93.65M) | $82.54M | $50.00M |
| Gross Margin %(computed) | -94.12% | 100.00% | -147.41% | 85.71% | 89.52% |
| Operating Expenses | |||||
| R&D Expenses | $107.83M | $135.00M | $172.60M | $320.45M | $215.52M |
| G&A Expenses | $46.52M | $74.17M | $81.45M | $84.23M | $57.32M |
| Total Operating Expenses | $141.45M | $223.91M | $96.86M | $390.93M | $266.99M |
| Operating Income | ($147.70M) | ($210.28M) | ($190.51M) | ($308.39M) | ($216.99M) |
| Operating Margin %(computed) | — | — | -299.86% | -320.23% | -388.56% |
| Interest Income | $11.05M | $17.29M | $17.19M | $5.84M | $1.31M |
| Interest Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Income Before Tax | ($136.31M) | ($186.26M) | ($160.93M) | ($281.72M) | ($212.15M) |
| Income Tax Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Income | ($136.31M) | ($186.26M) | ($160.93M) | ($281.72M) | ($212.15M) |
| Net Margin %(computed) | — | — | -253.30% | -292.55% | -379.89% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-1.15 | $-1.64 | $-1.64 | $-2.91 | $-2.24 |
| Wtd Avg Shares | 118.79M | 113.69M | 98.41M | 96.83M | 94.75M |
| EBITDA | ($127.02M) | ($176.58M) | ($172.23M) | ($294.63M) | ($211.14M) |
| EBITDA Margin %(computed) | — | — | -271.09% | -305.95% | -378.08% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · M
Explore more Fate Therapeutics, Inc. data
About Fate Therapeutics, Inc. (FATE) Income Statement
Fate Therapeutics, Inc. (FATE) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, FATE reported revenue of $0.01B, gross profit of ($0.01B) (gross margin -94.12%), and net income of ($0.14B) — a net profit margin of -2051.08%.
Frequently asked questions
FATE · 4 questionsFate Therapeutics, Inc. (FATE) reported revenue of $0.01B for 2025, down 51.2% year-over-year.
FATE revenueFATE salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09